BioSpace News Archive

Portage Biotech plans to distribute as stock dividend, a substantial part of the 6,341,500 common shares it holds in Biohaven Pharma.

Revenues of €6.0 million, an increase of 4.6% compared to 2016

Cash flow provided by operations for the six months ended September 30, 2017, was $138.7 million compared to $192.7 million for the six months ended September 30, 2016.

Sales of bio-succinic acid were $3.3M, compared to $3.7M in Q3 2016.

Revenue of $83.9M in the third quarter of 2017, an increase of 24.9%, or 24.1% in constant currency1, over the third quarter of 2016.

As a leading supplier of research products and custom services to global academic, pharmaceutical and biotech communities, Creative Diagnostics has introduced new treponema pallidum antigens for the diagnosis of syphilis, including recombinant T. Pallidum TpN47, T. Pallidum Major Membrane Immunogen p15 and T.

H&A Scientific will introduce version 5.0.0 of SLIM at the American Association of Pharmaceutical Scientists Annual Meeting, Nov. 12-15, in San Diego.

Cash, cash equivalents and investments totaled $116.7 million as of September 30, 2017, which includes net proceeds of $80.2 million from the company’s initial public offering completed in January 2017, compared to $51.2 million as of December 31, 2016.

For the three months ended September 30, 2017, revenues increased to $8.8 million from $7.8 million in the third quarter of 2016.

The share buyback program has been initiated in order to reduce the company’s share capital and to cover obligations under the long-term incentive program.